 |
|
|
| |
Characteristics of HIV+ Patients Prescribed Raltegravir
QD in the United States - good picture of the aging generation
|
| |
| |
this analysis provides a look at the Aging Generation:
Patient demographic characteristics at the time of RAL QD initiation are shown in Figure 1, stratified by baseline treatment status. The majority of patients were ≥50 years of age (57.8%), male (77.6%), and not Hispanic (82.0%). A total of 44.1% were African American. ......86% of patients had at least one of the comorbidities depicted in Figure 3 with hypertension being the most common (45.7%) followed by hyperlipidemia (41.3%), anemia (26.7%), anxiety disorders (25.2%) and diabetes (19.6%)......At the time of RAL QD initiation, almost two-thirds of the study population had ≥2 comorbidities, 28.9% had ≥4 comorbidities and 7.5% had ≥6 of the comorbidities detailed in Figure 3. The distribution of comorbidity frequency in the study population is illustrated in Figure 4......25% had anxiety disorders, 16% substance abuse, 13.7% depression, 11.5% CVD, 9% chronic liver disease, 9% HCV cured, 9% cancer, 7.5% HBV, 7% Schizophrenia/Bipolar/Manic Disorder, 1.5% moderate/severe chronic kidney disease.....The median number of prescriptions for concomitant medications prescribed with RAL QD regimens was 5.5 (IQR: 4-8). The most frequent concurrently prescribed drug classes were lipid lowering agents (28.3%), anti-depressant agents (23.0%), anti-diabetic agents (14.3%), antibiotics (10.6%) and immunomodulators (11.2%), 5% NSAIDS, 9.9% sedatives/hypnotics. Figure 5 depicts the distribution of co-medications by drug class.
Reported by Jules Levin
IDWeek; San Francisco, CA; October 3-7, 2018
Philip Lackey1, Kathy L. Schulman2, Jennifer Fusco2, Jean Marie Arduino3, Girish Prajapati3, Gregory Fusco2
1Atrium Health, Charlotte, NC; 2Epividian, Inc., Durham, NC; 3Merck & Co., Inc., Kenilworth, NJ, USA
VACS Mortality Index: Scored by summing pre-assigned points for age, CD4 count, HIV-1 RNA, hemoglobin, platelets, aspartate and alanine transaminase, creatinine, and viral hepatitis C infection. A higher score is associated with a higher risk of 5-year all-cause mortality. **Categories are not mutually exclusive as patients may have exposure to multiple core agents.
---------------------------------
The VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) Study
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965438/
|
| |
|
|
|
|
|
